09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio ( IBRX ).

Price: 6.39, Change: +0.15, Percent Change: +2.49